Nuclear Medicine and Biology
Volume 37, Issue 5 , Pages 527-537 , July 2010

In vitro structure–activity relationship of Re-cyclized octreotide analogues

  • Shorouk F. Dannoon

      Affiliations

    • Department of Chemistry, University of Missouri, Columbia, MO 65211, USA
    • S. Dannoon and H. Bigott-Hennkens contributed equally to this work.
    • ,
  • Heather M. Bigott-Hennkens

      Affiliations

    • Department of Veterinary Medicine and Surgery, University of Missouri, Columbia, MO 65211, USA
    • S. Dannoon and H. Bigott-Hennkens contributed equally to this work.
    • ,
  • Lixin Ma

      Affiliations

    • Department of Radiology, University of Missouri, Columbia, MO 65211, USA
    • International Institute of Nano and Molecular Medicine, University of Missouri, Columbia, MO 65211, USA
    • Nuclear Science and Engineering Institute, University of Missouri, Columbia, MO 65211, USA
    • Research Service, Harry S. Truman Memorial Veterans' Hospital, Columbia, MO 65201, USA
    • ,
  • Fabio Gallazzi

      Affiliations

    • Structural Biology Core, University of Missouri, Columbia, MO 65211, USA
    • ,
  • Michael R. Lewis

      Affiliations

    • Department of Veterinary Medicine and Surgery, University of Missouri, Columbia, MO 65211, USA
    • Department of Radiology, University of Missouri, Columbia, MO 65211, USA
    • Nuclear Science and Engineering Institute, University of Missouri, Columbia, MO 65211, USA
    • Research Service, Harry S. Truman Memorial Veterans' Hospital, Columbia, MO 65201, USA
    • Corresponding Author InformationCorresponding authors. Silvia S. Jurisson is to be contacted at the Department of Chemistry, University of Missouri, Columbia, MO 65211, USA. Tel.: +1 573 882 2107; fax: +1 573 882 2754. Michael R. Lewis, Department of Veterinary Medicine and Surgery, University of Missouri, MO 65211, USA. Tel.: +1 573 814 6000x53703; fax: +1 573 814 6551.
    • ,
  • Silvia S. Jurisson

      Affiliations

    • Department of Chemistry, University of Missouri, Columbia, MO 65211, USA
    • Department of Radiology, University of Missouri, Columbia, MO 65211, USA
    • Nuclear Science and Engineering Institute, University of Missouri, Columbia, MO 65211, USA
    • Corresponding Author InformationCorresponding authors. Silvia S. Jurisson is to be contacted at the Department of Chemistry, University of Missouri, Columbia, MO 65211, USA. Tel.: +1 573 882 2107; fax: +1 573 882 2754. Michael R. Lewis, Department of Veterinary Medicine and Surgery, University of Missouri, MO 65211, USA. Tel.: +1 573 814 6000x53703; fax: +1 573 814 6551.

Received 20 January 2010 ,Revised 2 March 2010 ,Accepted 27 March 2010.

References 

  1. Hofland LJ, Lamberts SWJ. The pathophysiological consequences of somatostatin receptor internalization and resistance. Endocr Rev. 2003;24(1):28–47
  2. Patel YC. Somatostatin and its receptor family. Front Neuroendocrinol. 1999;20(3):157–198
  3. Bauer W, Briner U, Doepfner W, Haller R, Huguenin R, Marbach P, et al. SMS 201-995: a very potent and selective octapeptide analog of somatostatin with prolonged action. Life Sci. 1982;31(11):1133–1140
  4. de Herder WW, Hofland LJ, van der Lely AJ, Lamberts SWJ. Somatostatin receptors in gastroentero–pancreatic neuroendocrine tumours. Endocr-Relat Cancer. 2003;10(4):451–458
  5. Lamberts SWJ, van Der Lely A-J, de Herder WW, Hofland LJ. Octreotide. N Engl J Med. 1996;334(4):246–254
  6. Olsen JO, Pozderac RV, Hinkle G, Hill T, O'Dorisio TM, Schirmer WJ, et al. Somatostatin receptor imaging of neuroendocrine tumors with indium-111 pentetreotide (Octreoscan). Semin Nucl Med. 1995;25(3):251–261
  7. Gotthardt M, Boermann OC, Behr TM, Behe MP, Oyen WJG. Development and clinical application of peptide-based radiopharmaceuticals. Curr Pharm Des. 2004;10(24):2951–2963
  8. Decristoforo C, Cholewinski W, Donnemiller E, Riccabona G, Moncayo R, Mather SJ. Detection of somatostatin receptor-positive tumors using the new 99mTc-tricine-HYNIC-D-Phe1-Tyr3-octreotide: first results in patients and comparison with 111In-DTPA-D-Phe1-octreotide. Eur J Nucl Med. 2000;27(10):1580
  9. Gabriel M, Decristoforo C, Donnemiller E, Ulmer H, Rychlinski CW, Mather SJ, et al. An intrapatient comparison of 99mTc-EDDA/HYNIC-TOC with 111In-DTPA-octreotide for diagnosis of somatostatin receptor-expressing tumors. J Nucl Med. 2003;44(5):708–716
  10. Giblin MF, Jurisson SS, Quinn TP. Synthesis and characterization of rhenium-complexed alpha-melanotropin analogs. Bioconjug Chem. 1997;8(3):347–353
  11. Chen J, Cheng Z, Hoffman TJ, Jurisson SS, Quinn TP. Melanoma-targeting properties of 99mtechnetium-labeled cyclic alpha-melanocyte-stimulating hormone peptide analogues. Cancer Res. 2000;60(20):5649–5658
  12. Chen J, Cheng Z, Owen NK, Hoffman TJ, Miao Y, Jurisson SS, et al. Evaluation of an 111In-DOTA-rhenium cyclized alpha-MSH analog: a novel cyclic-peptide analog with improved tumor-targeting properties. J Nucl Med. 2001;42(12):1847–1855
  13. Cheng Z, Chen J, Quinn TP, Jurisson SS. Radioiodination of rhenium cyclized alpha-melanocyte-stimulating hormone resulting in enhanced radioactivity localization and retention in melanoma. Cancer Res. 2004;64(4):1411–1418
  14. Bigott-Hennkens HM, Junnotula S, Ma L, Gallazzi F, Lewis MR, Jurisson SS. Synthesis and in vitro evaluation of a rhenium-cyclized somatostatin derivative series. J Med Chem. 2008;51(5):1223–1230
  15. Bigott-Hennkens HM, Dannoon SF, Figueroa SD, Hoffman TJ, Jurisson SS, Lewis MR. Biodistribution and imaging studies of somatostatin receptors using technetium-99m-cyclized tyrosine-3-octreotate. In:  Mazzi U editors. Technetium, Rhenium and Other Metals in Chemisty and Nuclear Medicine. vol. 7:Padova, Italy: SGE Editoriali; 2006;p. 295–300
  16. Grove DE, Wilkinson G. Oxo-complexes of rhenium(V). J Chem Soc A, Inorg Phys Theoret. 1966;(9):1224–1230
  17. Lis T, Jezowska-Trzebiatowska B. Preparation of oxopentachlororhenate(VI) and oxotetrachlororhenate(V). The crystal and molecular structure of AsPh4ReOCl4. Acta Crystallogr B. 1977;B33(4):1248–1250
  18. Pearson DA, Lister-James J, McBride WJ, Wilson DM, Martel LJ, Civitello ER, et al. Somatostatin receptor-binding peptides labeled with technetium-99m : chemistry and initial biological studies. J Med Chem. 1996;39(7):1361–1371
  19. Cyr JE, Pearson DA, Wilson DM, Nelson CA, Guaraldi M, Azure MT, et al. Somatostatin receptor-binding peptides suitable for tumor radiotherapy with Re-188 or Re-186. Chemistry and initial biological studies. J Med Chem. 2007;50(6):1354–1364
  20. Delaglio F, Grzesiek S, Vuister GW, Zhu G, Pfeifer J, Bax A. NMRPipe: a multidimensional spectral processing system based on UNIX pipes. J Biomol NMR. 1995;6(3):277–293
  21. Wishart DS, Bigam CG, Yao J, Abildgaard F, Dyson HJ, Oldfield E, et al. 1H, 13C and 15N chemical shift referencing in biomolecular NMR. J Biomol NMR. 1995;6(2):135–140
  22. Breeman WAP, de Jong M, Visser TJ, Erion JL, Krenning EP. Optimizing conditions for radiolabeling of DOTA-peptides with 90Y, 111In and 177Lu at high specific activities. Eur J Nucl Med Mol Imaging. 2003;30(6):917–920
  23. Smith CJ, Gali H, Sieckman GL, Higginbotham C, Volkert WA, Hoffman TJ. Radiochemical investigations of 99mTc-N3S-X-BBN[7-14]NH2: an in vitro/in vivo structure–activity relationship study where X=0-, 3-, 5-, 8-, and 11-carbon tethering moieties. Bioconjug Chem. 2003;14(1):93–102
  24. Ma L, Jones CT, Groesch TD, Kuhn RJ, Post CB. Solution structure of dengue virus capsid protein reveals another fold. Proc Natl Acad Sci USA. 2004;101(10):3414–3419
  25. Schwieters CD, Kuszewski JJ, Tjandra N, Marius Clore G. The Xplor-NIH NMR molecular structure determination package. J Magn Reson. 2003;160(1):65–73
  26. Giblin MF, Wang N, Hoffman TJ, Jurisson SS, Quinn TP. Design and characterization of alpha-melanotropin peptide analogs cyclized through rhenium and technetium metal coordination. Proc Natl Acad Sci USA. 1998;95(22):12814–12818
  27. Grace CRR, Erchegyi J, Koerber SC, Reubi JC, Rivier J, Riek R. Novel sst2-selective somatostatin agonists. Three-dimensional consensus structure by NMR. J Med Chem. 2006;49(15):4487–4496
  28. Wuthrich K. In: NMR of Proteins and Nucleic Acids. New York: John Wiley & Sons; 1986;p. 166
  29. Wynants C, Tourwe D, Kazmierski W, Hruby VJ, Van Binst G. Conformation of two somatostatin analogs in aqueous solution. Study by NMR methods and circular dichroism. Eur J Biochem. 1989;185(2):371–381
  30. Wynants C, Van Binst G, Loosli HR. Hexapeptide analog of somatostatin, Sandoz 201-456. Conformational study in dimethylsulfoxide by 1D and 2D n.m.r. methods. Int J Pept Protein Res. 1985;25(6):622–627
  31. Wynants C, Van Binst G, Loosli HR. SMS 201-995, an octapeptide somatostatin analog. Assignment of the proton 500 MHz n.m.r. spectra and conformational analysis of SMS 201-995 in dimethylsulfoxide. Int J Pept Protein Res. 1985;25(6):615–621
  32. Wynants C, Van Binst G, Michel A, Zanen J. Assignment of the proton 500 MHz NMR spectra of a synthetic eight-membered ring analog of somatostatin in aqueous solution. Int J Pept Protein Res. 1985;26(6):561–567
  33. Widmer H, Widmer A, Braun W. Extensive distance geometry calculations with different NOE calibrations: new criteria for structure selection applied to Sandostatin and BPTI. J Biomol NMR. 1993;3(3):307–324
  34. Pohl E, Heine A, Sheldrick GM, Dauter Z, Wilson KS, Kallen J, et al. Structure of octreotide, a somatostatin analog. Acta Crystallogr D Biol Crystallogr. 1995;D51(1):48–59
  35. Melacini G, Zhu Q, Goodman M. Multiconformational NMR analysis of Sandostatin (octreotide): equilibrium between beta-sheet and helical structures. Biochemistry. 1997;36(6):1233–1241

☆ Funding support was provided by NIH grant numbers DHHS1 F32 CA119894 (HMB-H) and DHHS1 P50 CA103130 (SSJ and MRL; WA Volkert, PI).

PII: S0969-8051(10)00065-X

doi: 10.1016/j.nucmedbio.2010.03.008

Nuclear Medicine and Biology
Volume 37, Issue 5 , Pages 527-537 , July 2010

Article Tools

* Image Usage & Resolution